Table 5.
References for urinary 8-OHdG concentrations measured and computed GM (ng/mg creatinine) with immunological techniques in healthy (mean BMI > 25 and no known disease), adult (18+ years) participants.
| Reference | Study Group | Sample | Country | Sample Size | Mean Age | Female | Male | Smoking Status | MeanBMI | AM | IQR | Range | Median | Units (8-OHdG/Creatinine) | Computed GM (ng/mg Creatinine) | GSD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [82] | Cocorit communities | spot urine | Mexico | 10 | 45.9 | 5 | 5 | 30% | 27 | 8.2 ± 4.3 * | μg/g | 7 | 2 | |||
| [82] | Pueblo Yaqui communities | spot urine | Mexico | 15 | 35.3 | 9 | 6 | 7% | 26.7 | 5.7 ± 2.9 * | μg/g | 5 | 2 | |||
| [82] | Campo 47 | spot urine | Mexico | 15 | 39.5 | 10 | 5 | 40% | 29.8 | 5.7 ± 3.3 * | μg/g | 5 | 2 | |||
| [83] | Control group | spot urine | UK | 61 | 28.4 | 61 | 0 | 9% | 26 | 39.83 ± 2.92 ** | ng/mg | 35 | 2 | |||
| [55] | Healthy older group | 24 h urine | Canada | 12 | 71.8 | 0 | 12 | 0% | 28.8 | 7714 ± 1402 * | ng/g | 8 | 1 | |||
| [84] | Water group baseline value | spot urine | USA | 42 | 18–79 | 32 | 10 | 100% | 25.9 | 8.7 ± 1.3 ** | ng/mg | 5 | 3 | |||
| [84] | Green tea group baseline value | spot urine | USA | 35 | 18–79 | 27 | 8 | 100% | 26.5 | 10.8 ± 1.3 ** | ng/mg | 9 | 2 | |||
| [84] | Black tea baseline value | spot urine | USA | 43 | 18–79 | 31 | 12 | 100% | 26.7 | 9.5 ± 2.1 ** | ng/mg | 6 | 2 | |||
| [85] | Water group baseline value | spot urine | USA | 45 | 49.8 | 32 | 13 | 100% | 26.9 | 9.5 ± 1.3 ** | ng/mg | 6 | 3 | |||
| [85] | Black tea baseline value | spot urine | USA | 46 | 52.1 | 34 | 12 | 100% | 27.2 | 10.8 ± 2.5 ** | ng/mg | 7 | 2 | |||
| [85] | Green tea group baseline value | spot urine | USA | 42 | 51.6 | 32 | 10 | 100% | 27.2 | 8.7 ± 1.8 ** | ng/mg | 5 | 3 | |||
| [86] | Placebo group baseline value | 24 h urine | USA | 47 | 58.1 | 23 | 24 | 0% | 28.9 | 17.6 ± 10.4 * | ng/mg | 15 | 2 | |||
| [86] | Vit C group baseline value | 24 h urine | USA | 46 | 61.2 | 26 | 20 | 0% | 28.7 | 19.3 ± 9.3 * | ng/mg | 17 | 2 | |||
| [86] | Vit E group baseline value | 24 h urine | USA | 45 | 55.5 | 29 | 16 | 0% | 28.6 | 16.5 ± 8.4 * | ng/mg | 15 | 2 | |||
| [86] | Vit C + Vit E baseline value | 24 h urine | USA | 46 | 57.7 | 24 | 22 | 0% | 28.9 | 17.7 ± 9.5 * | ng/mg | 16 | 2 | |||
| [87] | Control group | 24 h urine | Finland | 100 | 65 | 46 | 54 | 18% | 27.7 | 24.3 ± 15.2 * | ng/mg | 21 | 2 | |||
| [88] | Control group | spot urine | Taiwan | 27 | 49 | 0 | 27 | 55.6% | 25.8 | 5 ± 4.92 * | µg/g | 4 | 2 | |||
| [89] | All population | spot urine | Japan | 90 | 52 | 60 | 30 | 0% | 25.2 | 5.8–23.2 | 0.90–48.0 | 9.3 | ng/mg | 9 | 3 | |
| [90] | Baseline value | spot urine | Canada | 28 | 68.5 | NA | NA | 0% | 27.1 | 10783 ± 5856 * | ng/g | 9 | 2 | |||
| [91] | control group baseline | spot urine | Spain | 23 | 30.42 | 23 | 0 | 0% | 25.32 | 9.29 ± 0.69 ** | ng/mg | 9 | 1 | |||
| [91] | DHA group baseline | spot urine | Spain | 23 | 29.97 | 23 | 0 | 0% | 25.62 | 9.81 ± 0.79 ** | ng/mg | 9 | 1 | |||
| [92] | Placebo group men | 24 h urine | Canada | 8 | 74.8 | 0 | 8 | 0% | 25.9 | 8329 ± 3032 * | ng/g | 8 | 1 | |||
| [92] | Placebo group women | 24 h urine | Canada | 10 | 68.3 | 10 | 0 | 0% | 25.2 | 11622 ± 4379 * | ng/g | 7 | 1 | |||
| [92] | Intervention group men baseline | 24 h urine | Canada | 11 | 71.8 | 0 | 11 | 0% | 27.8 | 7245 ± 2703 * | ng/g | 11 | 1 | |||
| [92] | Intervention group women baseline | 24 h urine | Canada | 10 | 69.5 | 10 | 0 | 0% | 25.5 | 7942 ± 3071 * | ng/g | 7 | 1 | |||
| [15] | Men group early morning | spot urine | Italy | 22 | 34 | 0 | 22 | 38.1% | 25.3 | 2.76–5.25 | 3.76 | ng/mg | 5 | 2 |
* SD; ** SEM.